Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Часто задаваемые вопросы
В каком секторе работает Immuneering Corporation Class A Common Stock (IMRX)?
Immuneering Corporation Class A Common Stock относится к сектору Здравоохранение.
Какова текущая цена акций Immuneering Corporation Class A Common Stock (IMRX)?
По последним данным, цена акций Immuneering Corporation Class A Common Stock составляет 5,30 $, предыдущее закрытие — 5,25 $. За последнюю торговую сессию акции Immuneering Corporation Class A Common Stock выросли на 0,05 $, что соответствует росту на 0,95%.
Выплачивает ли Immuneering Corporation Class A Common Stock (IMRX) дивиденды?
Нет, Immuneering Corporation Class A Common Stock не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Immuneering Corporation Class A Common Stock (IMRX)?
У компании Immuneering Corporation Class A Common Stock бета 0.368, что указывает на более низкую волатильность по сравнению с рынком в целом.
